Search

Your search keyword '"Dito, E."' showing total 27 results

Search Constraints

Start Over You searched for: Author "Dito, E." Remove constraint Author: "Dito, E."
27 results on '"Dito, E."'

Search Results

1. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer

3. 451 Correlative and updated clinical endpoint analysis of a multicenter phase II trial of selumetinib (AZD6244) plus erlotinib in chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC)

5. AMINO TERMINAL NATRIURETIC PEPTIDES AND ASSOCIATION TO GLOBAL CARDIOVASCULAR RISK IN A MALE ADULT POPULATION FROM SOUTHERN ITALY

10. Abstracts

16. Sacubitril/valsartan: preliminary experience in post-acute stabilized patients with reduced ejection fraction heart failure.

17. T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.

18. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.

19. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.

20. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.

21. A survey on blood pressure levels and hypertension control in a sample of the Italian general population.

22. IGF-1 and atherothrombosis: relevance to pathophysiology and therapy.

23. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.

24. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

25. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

26. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

27. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Catalog

Books, media, physical & digital resources